March 10 (Reuters) - The U.S. Food and Drug Administration late on
Friday approved Acadia Pharmaceuticals Inc's drug for the treatment of
Rett syndrome, a genetic brain disorder, the company said, making it the
first-approved drug for the condition.
(Reporting by Bhanvi Satija, Nandhini Srinivasan and Anirudh Saligrama in
Bengaluru; Editing by Shailesh Kuber and William Mallard)
Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.